

KYBORA secures \$336M China licensing deal for Daewoong's IPF compound with CS-Pharma



LICENSING OF BERSIPOROCIN
TO CS PHARMA \$336M



KYBORA helps Daewoong license the China rights of its early stage IPF compound to CS-Pharma for \$336M, including \$76M in upfront and development milestones payments.

The Challenge

In January 2022, Daewoong, a leading South Korean pharmaceutical company, reached out to KYBORA to assist them with licensing DWN12088, an early-stage Idiopathic Pulmonary Fibrosis (IPF) to CS Pharma. Specifically, Daewoong needed to ensure that the terms it was receiving from CS Pharma were appropriate.

The Solution

KYBORA performed a complete market assessment including primary and secondary research, evaluation of regulatory pathways in China, pricing and reimbursement, and time to market. All this information was then included in KYBORA's proprietary deal valuation model which allowed Daewoong to make its decision.

The Outcome

Daewoong signed a lucrative licensing agreement that will help it bring a differentiated IPF product to patients in China. The model KYBORA built allowed them to sign a win-win agreement with CS Pharma.

To learn more, please reach
out to us at

info@kybora.com

KYBORA's mission is to help Life Sciences companies achieve enduring success. We provide M&A, Licensing, Fundraising and Strategic Consulting services to the global Biopharma industry, creating value for our Clients worldwide.

kybora.com

